Adamis Pharmaceuticals Corporation
http://www.adamispharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adamis Pharmaceuticals Corporation
New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
From Decoupling To Delisting: Might Biden-Xi Talks Ease Biotech Overhang?
While a two-hour-plus online discussion between the leaders of the world's two largest economies had some encouraging signs for the biopharma sector, more remains to be done and multiple other factors are playing into a mix of decoupling pressures.
Finance Watch: Big Money For Private Biopharma As Start-Up Areteia Raises $350m
Private Company Edition: As venture capital funding continues at a robust pace relative to public company financings, Knopp Biosciences and Population Health Partners launched Areteia with enough cash to fund Phase III asthma trials and Qiming revealed new VC funds totaling $2.5bn and $700m.
US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?
It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Biosyn Inc.
- Cellegy Holdings Inc
- US Compounding, Inc.